GlassScriptPhysician profile
Whitney Pritham
NPI 1386651347
$779.39
in general payments reported to CMS, 2019-2025
22 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $155 · 2023: $206 · 2024: $196 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.32 |
| Education | $149.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $131.18 | 2023-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $105.01 | 2023-2025 | Enhertu, Imfinzi |
| Aveo Pharmaceuticals, INC. | $98.92 | 2022-2024 | |
| Janssen Biotech, INC. | $85.99 | 2025 | Talvey, Tecvayli, Darzalex |
| Genzyme Corporation | $30.35 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $28.23 | 2023 | Imbruvica, Epkinly |
| Seagen INC. | $23.86 | 2022 | |
| Abbvie INC. | $22.86 | 2025 | |
| Aadi Bioscience, INC. | $22.36 | 2025 | Fyarro |
| Janssen Scientific Affairs, LLC | $21.06 | 2022 | |
| Genentech USA, INC. | $20.94 | 2024 | Rozlytrek, Alecensa, Tecentriq |
| E.R. Squibb & Sons, L.L.C. | $20.66 | 2024 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $19.69 | 2024 | Libtayo |
| Incyte Corporation | $19.60 | 2025 | Monjuvi, Zynyz |
| Jazz Pharmaceuticals INC. | $19.49 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $17.79 | 2024 | Orserdu |
| Novocure INC. | $16.25 | 2022 | |
| Glaxosmithkline, LLC. | $15.76 | 2025 | Ojjaara |
| Astellas Pharma US INC | $15.61 | 2023 | Padcev |
| Gilead Sciences, INC. | $14.94 | 2024 | |
| Eusa Pharma (US) LLC | $14.74 | 2022 | |
| Sobi, INC | $14.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Pritham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.